Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-ranging study of ABBV-154 in glucocorticoid-dependent polymyalgia rheumatica
2021-000648-23Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing ABBV-154 with Placebo (2 arms). Primary endpoint: Time to flare. Started Jul 2021; status: terminated.
02
Drugs
ABBV-154
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on 2021-000648-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000648-23.